A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program

Background

Inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), are increasingly prevalent. Ustekinumab (UST), a biologic therapy, has shown efficacy in treating CD and UC, but its real-world impact is less clear. This study assessed all-cause and IBD-specific healthcare resource utilization (HCRU) and costs, excluding medication costs, among patients with CD and UC initiated on UST.